Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Vomiting 1Opioid-Related Disorders 1Nausea 1

Interventions

Magnetic Resonance Spectroscopy 84Specimen Handling 83Cyclophosphamide 75pembrolizumab 64Radiotherapy 54Nivolumab 52fludarabine 44Cisplatin 40Biopsy 40Carboplatin 39Standard of Care 38Bevacizumab 32Dexamethasone 31Rituximab 29Gemcitabine 29venetoclax 27Surveys and Questionnaires 27Radiosurgery 27Radiation 27Temozolomide 26Practice Guidelines as Topic 26Paclitaxel 25Doxorubicin 25Blood Specimen Collection 25Cytarabine 24fludarabine phosphate 23Interviews as Topic 22atezolizumab 21Injections 20Capecitabine 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Olanzapine × 30 days × Clear all
NCT06200181 2026-06-01

Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial

M.D. Anderson Cancer Center

Phase 3 Recruiting
87 enrolled

Opioid-Related Disorders

NCT07403370 2026-05-19

Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis

Shandong Cancer Hospital and Institute

Completed
2,000 enrolled

Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡